Mirum Pharmaceuticals to Announce Second Quarter 2026 Financial Results and Host Conference Call on August 5, 2026
Mirum Pharmaceuticals and Incyte Announce Positive Pivotal Phase 2 Results from PROGRESS Study of Zilurgisertib in Fibrodysplasia Ossificans Progressiva
Mirum Pharmaceuticals Announces New Data from Rare Liver Disease Programs Presented at the EASL International Liver Congress 2026
Mirum Pharmaceuticals to Present Data Showcasing Leadership in Rare Liver Diseases at the EASL International Liver Congress 2026
Mirum Pharmaceuticals Prices $600.0 Million Convertible Senior Notes Offering; Refinances a Portion of 2029 Convertible Notes
Mirum Pharmaceuticals Announces Primary Endpoint Met in VISTAS Study of Volixibat in Patients with Primary Sclerosing Cholangitis
Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the VISTAS Study of Volixibat in Patients with Primary Sclerosing Cholangitis on May 4, 2026
Mirum Pharmaceuticals to Announce First Quarter 2026 Financial Results and Host Conference Call on May 6, 2026
Mirum Pharmaceuticals Announces Primary Endpoint Met in Phase 2b Portion of the AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta Virus
Mirum Pharmaceuticals Provides AZURE Clinical Program Update for brelovitug in Chronic Hepatitis Delta Virus
Lithium Argentina Announces Cauchari-Olaroz Stage 2 Scoping Study Results and Acceleration of Initial Phase of 10,000 tpa
TomaGold Continues to Intersect Wide Zones of Zinc, Gold and Silver on Optioned Chibougamau Independent Claims
Angkor Resources' Subsidiary Receives Ministry of Environment Approval to Drill Four Sub-Basins on Block VIII, Cambodia
Copper Intelligence and CoTec Finalise Joint Venture Shareholder Agreement to Target Processing Historical Copper Tailings Opportunities in the Democratic Republic of Congo
